While these agents effectively inhibit acetylcholinesterase activity at the neuromuscular junction, they demonstrate significantly reduced clinical benefit in MuSK-positive MG, as the primary pathophysiology involves antibody-mediated disruption of MuSK-dependent postsynaptic signaling rather than solely acetylcholine deficiency. The gene discussed is ACHE; the disease is myasthenia gravis.